With new data, Regenxbio to seek FDA approval of Duchenne gene therapy

Regenxbio is moving forward with plans to seek FDA approval for its gene therapy targeting Duchenne muscular dystrophy, despite encountering two serious side effects during trials. CEO Curran Simpson remains optimistic about the approval process, citing a potential mandate from FDA leadership that could favor flexibility in rare disease treatments.